|
Jan 28
|
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
|
|
Jan 27
|
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
|
|
Jan 24
|
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
|
|
Jan 24
|
Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33?
|
|
Jan 24
|
Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns
|
|
Jan 22
|
Revenues, Treatment Pipeline Driving Exelixis Higher
|
|
Dec 31
|
Exelixis price target raised to $38 from $34 at RBC Capital
|
|
Dec 30
|
High Growth Tech Stocks to Watch in December 2024
|